Grifoxina

Grifoxina is a prescription medication that contains the active ingredient levetiracetam. It is supplied in an oral dosage form and is marketed in the European Union. Levetiracetam belongs to the antiepileptic drug class and works by modulating neurotransmitter release to help control various types of seizures.

Grifoxina is indicated for the treatment of several seizure disorders in patients who require an oral antiepileptic agent.

- Management of partial-onset seizures, with or without secondary generalization. - Control of generalized tonic-clonic seizures in adults and adolescents. - Treatment of myoclonic seizures, particularly in juvenile myoclonic epilepsy. - Adjunctive therapy for refractory epilepsy when other medications are insufficient. - Use as monotherapy or in combination with other antiepileptic drugs as directed by a healthcare professional.

Levetiracetam may cause a range of side effects, some of which are more frequently observed than others.

Common: - Dizziness or light‑headed feeling. - Fatigue or generalized tiredness. - Headache, often mild to moderate. - Irritability or mood changes. - Nausea or mild gastrointestinal discomfort. - Nasal congestion or runny nose.

Serious: - Severe allergic reactions such as rash, swelling, or difficulty breathing. - Mood disturbances including depression, anxiety, or suicidal thoughts. - Unusual changes in behavior or aggression. - Severe skin reactions like Stevens‑Johnson syndrome. - Hematologic abnormalities such as low blood cell counts. - Hepatic dysfunction indicated by jaundice or elevated liver enzymes.

Before starting Grifoxina, patients should consider several safety factors and discuss them with their prescriber.

- Review any history of psychiatric disorders, as levetiracetam can affect mood. - Inform the clinician of any renal impairment; dosage may need adjustment. - Discuss pregnancy plans, because the safety profile during pregnancy is not fully established. - Report any signs of allergic reaction promptly. - Avoid abrupt discontinuation; tapering may be required to prevent seizure worsening. - Use caution when operating machinery or driving until individual response is known.

Levetiracetam may interact with other medications, influencing its effectiveness or safety.

Avoid: - Concurrent use with strong enzyme‑inducing antiepileptics that may reduce levetiracetam levels. - Combining with drugs that significantly prolong the QT interval. - Co‑administration with medications known to cause severe hypersensitivity reactions.

Use with caution: - Other central nervous system depressants, which may increase sedation. - Antidepressants or antipsychotics, due to potential mood‑related effects. - Renally cleared drugs, as altered kidney function can affect drug concentrations. - Hormonal contraceptives, although levetiracetam generally has minimal impact, monitoring is advised.